当前位置: 首页 >> 检索结果
741. Tofacitinib in combination with glucocorticoids in the treatment of eosinophilic granulomatosis with polyangiitis: a pilot study of 11 cases.
作者: Yun Liu.;Minglang Zhan.;Rongyi Chen.;Xianting Sun.;Mengdi Li.;Huiyong Chen.;Lindi Jiang.
来源: Rheumatology (Oxford). 2025年64卷12期6294-6301页
Current treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is not always satisfactory due to refractory disease, relapse and drug toxicity. This study aims to investigate the efficacy and safety of tofacitinib, a Janus kinase (JAK) inhibitor, in the treatment of EGPA.
742. Impaired humoral and T helper cell responses to toxic shock syndrome toxin-1 (TSST-1) in granulomatosis with polyangiitis.
作者: Hang Liao.;Abraham Rutgers.;Minke G Huitema.;Caroline Roozendaal.;Peter Heeringa.;Wayel H Abdulahad.
来源: Rheumatology (Oxford). 2025年64卷12期6309-6318页
Nasal carriage of toxic shock syndrome toxin-1 (TSST-1)-positive Staphylococcus aureus (SA) is associated with a high relapse rate in granulomatosis with polyangiitis (GPA), suggesting TSST-1's role in disease progression. This study investigated the immune response to S. aureus-derived TSST-1 and characterized TSST-1-specific Th cells in GPA patients.
743. Aquaporin-4 downregulation in dysphagic patients with idiopathic inflammatory myopathies: myofiber vulnerability and inflammation drivers.
作者: Marco Fornaro.;Margherita Giannini.;Dario D'Abbicco.;Maria L Fiorella.;Mariella Errede.;Daniela Virgintino.;Onofrio Valente.;Antonio Frigeri.;Florenzo Iannone.;Francesco Girolamo.
来源: Rheumatology (Oxford). 2025年64卷12期6378-6386页
To evaluate whether the impairment of aquaporin-4 (AQP4), a water channel protein important for muscle function, may be associated with dysphagia in idiopathic inflammatory myopathies (IIMs). Swallowing muscle inflammation in IIM has been documented in case reports, but direct correlations with limb muscles impairment are lacking.
744. Urinary soluble CD163 is useful to predict lupus nephritis activity and to monitor standard-of-care therapy response.
作者: Yves Renaudineau.;Emmanuel Treiner.;Magali Colombat.;Gregory Pugnet.;Laurent Sailler.;Antoine Huart.;Stanislas Faguer.;Julie Belliere.
来源: Rheumatology (Oxford). 2025年64卷12期6319-6327页
This study aims to assess urinary soluble CD163 normalized to creatinuria (usCD163/Cre) alongside conventional biomarkers as indicators of renal activity and therapeutic response in LN.
746. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus - Authors' reply.
作者: Melanie Hagen.;Fabian Müller.;Andreas Wirsching.;Soraya Kharboutli.;Silvia Spoerl.;Christina Düsing.;Tobias Krickau.;Markus Metzler.;Simon Völkl.;Michael Aigner.;Sascha Kretschmann.;Ingrid Vasova.;Marc Saake.;Stefan Schliep.;Torsten Kubacki.;Nicolas Hunzelmann.;Laura Bucci.;Jule Taubmann.;Christina Bergmann.;Andrea-Hermina Györfi.;Sascha Dietrich.;Jörg H W Distler.;Ricardo Grieshaber-Bouyer.;Andreas Mackensen.;Georg Schett.
来源: Lancet Rheumatol. 2025年7卷10期e667-e669页 750. Personalised gait retraining for medial compartment knee osteoarthritis: a randomised controlled trial.
作者: Scott D Uhlrich.;Valentina Mazzoli.;Amy Silder.;Andrea K Finlay.;Feliks Kogan.;Garry E Gold.;Scott L Delp.;Gary S Beaupre.;Julie A Kolesar.
来源: Lancet Rheumatol. 2025年7卷10期e708-e718页
Retraining individuals with medial compartment knee osteoarthritis to walk with a patient-specific change in their foot angle (ie, toe-in or toe-out angle) can reduce excessive joint loading related to disease progression. This study investigated the clinical, biomechanical, and structural efficacy of personalised foot progression angle modifications compared with sham treatment in patients with mild-to-moderate medial compartment knee osteoarthritis.
752. Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: a multicentre retrospective study.
作者: Arsène Mekinian.;Sarah Meneses.;Lucie Biard.;Lorenzo Dagna.;Pavel Novikov.;Carlo Salvarani.;Olivier Espitia.;Savino Sciscia.;Martin Michaud.;Marc Lambert.;José Hernández-Rodríguez.;Nicolas Schleinitz.;Abid Awisat.;Xavier Puéchal.;Achille Aouba.;Heloise Munoz Pons.;Ilya Smitienko.;Jean Baptiste Gaultier.;Le Mouel Edwige.;Ygal Benhamou.;Antoinette Perlat.;Patrick Jego.;Tiphaine Goulenok.;Karim Sacre.;Bertrand Lioger.;Nolan Hassold.;Jonathan Broner.;Virginie Dufrost.;Thomas Sene.;Julie Seguier.;Francois Maurier.;Sabine Berthier.;Alexandre Belot.;Faten Frikha.;Guillaume Denis.;Alexandra Audemard-Verger.;Isabelle Koné-Paut.;Sebastien Humbert.;Pascal Woaye-Hune.;Alessandro Tomelleri.;Elena Baldissera.;Masataka Kuwana.;Alberto Lo Gullo.;Vahan Mukuchyan.;Azeddine Dellal.;Francis Gaches.;Pierre Zeminsky.;Chiara Marvisi.;Moya Alvarado.;Luigi Boiardi.;Francesco Muratore.;Mathieu Vautier.;Corrado Campochiaro.;Sergey Moiseev.;Matheus Vieira.;Patrice Cacoub.;Olivier Fain.;David Saadoun.; .
来源: Rheumatology (Oxford). 2025年64卷12期6192-6200页
In this large multicentre study, we aimed to compare the effectiveness of intravenous infliximab (IFX) vs subcutaneous adalimumab (ADA) in patients with Takayasu arteritis (TAK).
754. A screening tool to detect interstitial lung disease in systemic sclerosis: the ILD-RISC score.
作者: Cosimo Bruni.;Lorenzo Tofani.;Håvard Fretheim.;Sophie I E Liem.;Arthiha Velauthapillai.;Hilde Bjørkekjær.;Imon Barua.;Ilaria Galetti.;Alexandru Garaiman.;Mike O Becker.;Anna-Maria Hoffmann-Vold.;Jeska de Vries-Bouwstra.;Madelon C Vonk.;Jörg H W Distler.;Marco Matucci-Cerinic.;Oliver Distler.
来源: Rheumatology (Oxford). 2025年64卷12期6285-6293页
As a screening tool for the presence of systemic sclerosis-associated interstitial lung disease (SSc-ILD) on high-resolution computed tomography (HRCT) is missing, we aimed to develop the ILD-RISC score, a risk algorithm to guide physicians in ordering HRCTs, with specific focus on follow-up visits.
755. Identification of a novel TGFB1 variant in a patient with Camurati-Engelmann disease responsive to alendronate.
作者: Neelam Hassan.;Celia L Gregson.;Michael Oldridge.;Tracy Lester.;Emma L Duncan.;Jonathan H Tobias.
来源: Rheumatology (Oxford). 2025年64卷12期6427-6429页 756. How early is early for JIA? Insights from the infantile-onset juvenile idiopathic arthritis patients of the PERA research group cohort.
作者: Kubra Ozturk.;Tuncay Aydin.;Gulcan Ozomay Baykal.;Esra Baglan.;Hulya Kose.;Hakan Kisaoglu.;Deniz Gezgin Yildirim.;Fatma Gul Demirkan.;Gulcin Otar Yener.;Mustafa Çakan.;Belde Kasap Demir.;Hatice Adiguzel Dundar.;Gulsah Kilbas.;Hafize Emine Sonmez.;Serkan Turkucar.;Balahan Bora.;Selcuk Yuksel.;Nuray Aktay Ayaz.;Sevcan Bakkaloglu.;Mukaddes Kalyoncu.;Sara Sebnem Kilic.;Semanur Ozdel.;Betul Sozeri.;Erbil Unsal.
来源: Rheumatology (Oxford). 2025年64卷12期6278-6284页
Juvenile idiopathic arthritis (JIA) is the most common chronic childhood arthritis, with distinct categories based on pathophysiology and clinical manifestations. The age of onset varies by category but is reported to be approximately six years. This study aimed to evaluate the clinical, laboratory and outcome characteristics of patients with infantile-onset JIA.
757. High ischemic deficit in computed tomography perfusion is a risk factor for cerebral vascular ischemic events in Takayasu arteritis: a prospective observational study.
Patients suffering from Takayasu arteritis (TA) with stenosis or occlusion of supra-aortic trunks carry a high risk of cerebral vascular ischemic events (CVIEs). We explored the relationship between cerebral blood perfusion and CVIEs in TA.
758. Patient characteristics and adverse effects of allogeneic blood transfusion following lower extremity joint replacement in rheumatoid arthritis: a nationwide inpatient sample database study.
作者: Wenyan Geng.;Lulu Ye.;Xuegao Yu.;Qinfeng Yang.;Linlin Wang.;Xiaodan Li.;Qing Xiao.;Jian Wang.
来源: BMC Rheumatol. 2025年9卷1期101页
Allogeneic blood transfusion is a common therapeutic intervention for patients with rheumatoid arthritis (RA) undergoing lower extremity joint replacement (LEJR). Despite the potential for adverse outcomes associated with blood transfusion, the risks related to this procedure in RA patients remain underexplored, particularly within the framework of a large-scale national dataset.
760. Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence.
作者: Andy Nolan.;Daniel M Foulkes.;Emma E Fairweather.;Michele Fresneda Alarcon.;Christina Linford.;Andrew Sellin.;Zoe McLaren.;Patrick A Eyers.;Helen L Wright.
来源: Rheumatology (Oxford). 2025年64卷12期6409-6414页
Activation of neutrophils and release of neutrophil extracellular traps (NETs), proteases and reactive oxygen species (ROS) is pathogenic in immune-mediated inflammatory diseases like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), driving inflammation and damaging host tissues. The aim of this research was to identify small molecule inhibitors of NET production using a highly curated panel of narrow-spectrum small molecule kinase inhibitors termed the kinase chemogenomic set (KCGS).
|